The insidious and lethal nature of cancer, associated with its unique characteristics of dedifferentiation and loss of specialist function, invasion, and metastasis, is the result of changes in the chemical nature and structure of the proteoglycans of the cell glycocalyx and lysosomal enzymes, resulting from alterations in the highly specific glycosylations of the glycosyl transferases of the endoplasmic reticulum (1-3). These changes in cell proteoglycans, among the earliest changes seen in malignancy and used for histological diagnoses of premalignant states (4), are not only highly characteristic of the disease but also contribute progressively to the full establishment of malignancy. Changes occur in the glycocalyx, resulting in loss of cell adhesion (5) or in open intercellular tight junctions, enabling toxic chemicals and reactive intermediates to reach the critical basal cells of epithelia. These changes may evoke permanent DNA damage, resulting in a malignant cell clone. Changes in cell adhesion result in metastasis (3,6), and changes in the proteoglycan hydrolases are associated with tissue invasion (7, 8) . It is not insignificant that these earliest changes in glycosyl transferase activities and proteoglycan synthesis occur in the endoplasmic reticulum, the major site of metabolite activation of chemical carcinogens and of the generation of reactive oxygen species (ROS) from the futile cycling of the microsomal cytochromes. Furthermore, the endoplasmic reticulum is believed to contain its own DNA.
The insidious and lethal nature of cancer, associated with its unique characteristics of dedifferentiation and loss of specialist function, invasion, and metastasis, is the result of changes in the chemical nature and structure of the proteoglycans of the cell glycocalyx and lysosomal enzymes, resulting from alterations in the highly specific glycosylations of the glycosyl transferases of the endoplasmic reticulum (1) (2) (3) . These changes in cell proteoglycans, among the earliest changes seen in malignancy and used for histological diagnoses of premalignant states (4) , are not only highly characteristic of the disease but also contribute progressively to the full establishment of malignancy. Changes occur in the glycocalyx, resulting in loss of cell adhesion (5) or in open intercellular tight junctions, enabling toxic chemicals and reactive intermediates to reach the critical basal cells of epithelia. These changes may evoke permanent DNA damage, resulting in a malignant cell clone. Changes in cell adhesion result in metastasis (3, 6) , and changes in the proteoglycan hydrolases are associated with tissue invasion (7, 8) . It is not insignificant that these earliest changes in glycosyl transferase activities and proteoglycan synthesis occur in the endoplasmic reticulum, the major site of metabolite activation of chemical carcinogens and of the generation of reactive oxygen species (ROS) from the futile cycling of the microsomal cytochromes. Furthermore, the endoplasmic reticulum is believed to contain its own DNA.
The categorization of cancer development into the phases of initiation, promotion, progression, and development is an oversimplistic approach, since cancer, like aging, is a process of continuous and progressive DNA degeneration (9, 10) (12, 13) . The activation of chemical carcinogens to reactive intermediates (ultimate carcinogens) is catalyzed primarily by cytochrome P4501 (CYPI) (14, 15) , which selectively accepts planar molecules (carcinogens) as substrates (16) ; oxygenates them in conformationally hindered positions, thus forming highly reactive epoxides, which, however, are not easily detoxified by epoxide hydrolase, glutathione transferase, and other detoxification enzymes (16) ; and is regulated by a cytosolic (steroidlike) receptor, the Ah receptor, which binds some carcinogens and other planar molecules to induce increased production of CYP1, Ah receptor protein, and other enzymes by genomal depression and also activates the protein kinase C cascade (14) . Although the majority of known carcinogenic chemicals are believed to be metabolically activated by CYP1, the nitrosamines and other small molecules are activated by cytochrome P4502E1 (17 Other mechanisms, including the action of prostaglandin synthetase (18) , myeloperoxidase, and ROS-mediated oxygenations, are known to be equally effective in carcinogen activation. However, the unique pivotal role of CYP1 in chemical carcinogenesis is due to its coordination with the regulatory Ah receptor, resulting in the normal, low, non-injurious tissue levels of CYP1 being greatly augmented (1000-fold or more) by enzyme induction (19) . Moreover, this enhanced metabolic activation of carcinogens by CYP1 to damage the DNA coincides with the activation of protein kinase C to augment DNA replication and evoke hyperplasia, thus ensuring that the faulty genetic information is preserved and perpetuated in a clone of DNA-damaged cells.
ROS can similarly damage DNA (20) and may also result in activation of protein kinase C, oncogene activation, and multistage carcinogenesis (21) . ROS are generated continuously in biological systems by the low efficiency in the conversion of chemical energy into work, the associated electron leakage from membranes, and the consequent reduction of 02 to superoxy anion and other ROS. As ROS generation depends on tissue 02 uptake, and this is high in small animal species, the spontaneous formation of ROS is greatest in small rodents (22) . Furthermore, biological systems have an antioxidant defense system to prevent ROS leading to oxidative stress, tissue damage, and mutations, and this is critically dependent on tissue glutathione concentrations. While small rodents, especially mice, consume tissue glutathione in chemical detoxification, humans and larger animals more expediently use water and epoxide hydrolase to detoxify carcinogenic epoxides, with the overall consequence that rats and mice are much more susceptible to the toxic effects (23) . Production of ROS may be greatly increased by futile cycling of the microsomal cytochromes P450; even phenobarbitone, which is regarded as a noncarcinogen and is metabolized by CYP2B, results in considerable ROS production, which can potentiate the malignancy of known carcinogens (e.g., dimethylnitrosamine).
The extreme case of P450 futile cycling is seen with cytochrome P4502E1 (CYP2E1), an enzyme which is believed to result in the oxygenation of difficult-tooxidize substrates (e.g., ethanol) by generating ROS in the vicinity of the substrate (24, 25) . Enhancement of CYP2E1 activity (by substrate-induced stabilization of the enzyme, not enzyme induction) leads to a prolonged burst of ROS production that can result in tissue necrosis, mutations, malignancy, organ failure, and death. Numerous chemicals are known to enhance CYP2E1 activity [e.g., ethanol, acetone, halothane, and many other small halogenated chemicals (26) ] and hence to provoke ROS generation with consequent toxicity and carcinogenicity in small rodents. Indeed, inspection has revealed that those chemicals that cause cancer in rodents, especially mice, but not in larger species, are mostly substrates of CYP2E1. For the reasons given, these chemicals are unlikely to result in oxidative stress in humans and larger animals species, and are therefore unlikely to constitute as serious a carcinogenic hazard as substrates of CYP1.
By using molecular parameters (molecular planarity, collision diameters, frontier orbital energies) that discriminate substrates of CYPI and CYP2E1 from each other and from those of other cytochromes, a novel procedure (COMPACT) has been developed to detect potential genotoxic carcinogens (CYP1 substrates) and rodent carcinogens (CYP2E1) (22, 27, 28) . The lack of concordance between the Ames test for mutagens (which detects mostly CYPI substrates) and the rodent two-species assay (which identifies both CYPI and CYP2E1 substrates) is thus explained. Apart from this development in cancer detection and prevention, the understanding of the multifactorial mechanisms of chemical carcinogenesis has facilitated new preventive measures and treatments, including inhibition of CYPI (29, 30) , enhanced detoxification of ROS (31, 32) , and dietary supplementation with antioxidant nutrients (31, 33, 34) .
